Introduction {#sec1}
============

Lung cancer is the most common cause of cancer death all over the world. Non-small-cell lung cancer (NSCLC) accounts for 85%--90% of the lung cancer cases.[@bib1], [@bib2] Conventional cancer therapies such as chemotherapeutics and radiation exhibit severe side-effects, including gastrointestinal distress, organ damage, and low-quality life.[@bib3], [@bib4] New therapies including those based on monoclonal antibodies and their combination with other approaches have gained momentum as targeted therapeutics.[@bib4], [@bib5] Over the past decades, great efforts have been made for the development of new targeted therapeutics to overcome the drawbacks associating with conventional therapies, among which epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are most commonly used for lung cancer treatment.[@bib6] These are used in advanced NSCLC patients harboring EGFR mutations and have greatly enhanced survival rate by decreasing the toxicity as compared with cytotoxic chemotherapy. Nevertheless, resistance invariably occurs,[@bib4], [@bib6], [@bib7] highlighting the need to explore other strategies for targeting therapy. Moreover, tumor-specific biomarkers for NSCLCs are rare. Most reported biomarkers are not only expressed on tumor cells but also on normal cells, thereby restricting their clinical applications. Thus, identification of novel biomarkers for NSCLC diagnosis and development of more effective targeted therapeutics are of great importance.

Aptamers are single-stranded nucleic acids well-folded into diverse structures to bind specific targets. Since their first use in the 1990s,[@bib8], [@bib9] many high-affinity aptamers that target small molecules to large proteins have been identified.[@bib10], [@bib11], [@bib12], [@bib13] In comparison to antibodies, aptamers display obvious advantages such as easy chemical synthesis, none or low immunogenicity, smaller molecular size, and efficient entry into biological compartments.[@bib14] Aptamers have been employed as drug carriers to deliver chemotherapeutics, small interfering RNAs (siRNAs), or nanoparticles into targeted tissues.[@bib13], [@bib15], [@bib16], [@bib17], [@bib18] Thus, aptamers may serve as targeting ligands to direct therapeutics to the tumor site for increasing the effective concentration of drugs while minimizing the side effects to non-targeted normal tissues.

Systematic evolution of ligands by exponential enrichment (SELEX) and cell-SELEX are the major methods employed for aptamer selection. After several rounds of selection, enriched sequences emerge as the candidates binding their targets. Further identification and characterization of these candidate sequences result in their application for diagnosis or targeted therapy. The recombinant proteins or cells utilized for SELEX may not mimic the necessary antigen state or folding *in vivo*, owing to varying antigen density, interaction, and microenvironment. As a result, some aptamers selected using *in vitro* selection may fail to perform favorably *in vivo*. Recent studies by Mi[@bib19] and Cheng[@bib20] identified RNA aptamers through *in vivo* evolution strategies, suggestive of the feasibility to screen the tumor-targeting aptamers within living animals.

In this study, we present a novel *in vivo* selection platform against NSCLC NCI-H460 tumor xenografted in nude mice. To improve the stability of the RNA pool for *in vivo* selection, we combined 2′-fluoropyrimidine modification together with polyethylene glycol (PEG, the process of PEGylation) before each selection round. After 11 selection rounds, an aptamer that specifically recognizes and inhibits NCI-H460 tumor was isolated. The aptamer was used as a carrier for targeted delivery of a chemotherapeutic, which enhanced the *in vitro* and *in vivo* cytotoxicity of the chemotherapeutic.

Results {#sec2}
=======

Direct *In Vivo* Selection of RNA Aptamer Using Xenograft Mouse Model {#sec2.1}
---------------------------------------------------------------------

We hypothesized the tumor *in vivo* to be an optimal platform as compared with *in vitro* targets to screen and generate RNA aptamers against NSCLC. NCI-H460-bearing xenograft nude mouse model was established for the selection. We started with a previously reported DNA library containing 40 random nucleotides flanked by consensus sequences at both 5′ and 3′ ends.[@bib21] The transcription of this DNA library can provide 10^14^ to 10^15^ unique RNA sequences, which were used for the selection process. To enhance the *in vivo* stability and circulatory half-life of RNA library in animals, 2′-fluoropyrimidines were incorporated during transcription using 2′-F-dCTP/dUTP, and 5′-PEGylation was performed in the entire selection process.[@bib22] The recovered RNA sequences were reversely transcribed, and the resulting complementary DNAs (cDNAs) were PCR amplified for the next round of selection or cloned and sequenced after every three rounds of selection to monitor the *in vivo* SELEX progress ([Figures 1](#fig1){ref-type="fig"}A and 1B). As illustrated in [Figure 1](#fig1){ref-type="fig"}C, nearly 60%∼70% of the RNAs were PEGylated with a shift band, ensuring the high diversity of the PEGylated RNA pool used in the selection. Following round 8, one RNA sequence (RA16) was identified as the most abundant sequence at a frequency of 21.2% by Sanger sequencing ([Table 1](#tbl1){ref-type="table"}). The secondary structure of RA16 was predicted by Mfold[@bib23] (version 3.1; online, <http://unafold.rna.albany.edu>). After several continuous selection rounds, RA16 dominated the pool by up to 94.7% (round 11) ([Table 1](#tbl1){ref-type="table"}), suggesting it is an aptamer that specifically binds to NCI-H460 tumor.Figure 1*In vivo* SELEX Strategy(A) Workflow of the *in vivo* SELEX screening. The *in vitro* transcribed and PEGylated RNA pools were injected into the NCI-H460 tumor-bearing mice. Tumors were harvested, and RNAs trapped in the tumor were isolated and subjected to RT-PCR and *in vitro* transcription. After every three rounds of selection, the recovered DNA pool was cloned and sequenced for further analysis. (B) Schematic of PEGylation of aminated RNAs with NHS-PEG. (C) Analysis of RNA PEGylation on 3% agarose gel.Table 1Recovered Sequence from *In Vivo* Selection PlatformDNA Library: CACTAATACGACTCACTATAGGGAGAGAACAATGACCT[N(40)]{.ul}GAGTGCATTGCATCACGTCAGTAGRNA PoolTop Five Sequences (40 nt Random Region, 5′→3′)Frequency (%)Round 8 (Sanger sequencing, 33 colonies)[GCGGTGCCAAGCCGTCGGGTTATGTTGATCTCCTCAAGGAC]{.ul}21.2GACCGGAGGCCTAGCCAAACCGGACCGCTTAATGACTCTCA6.1GTACTACCCCACAAGAGGCTAGATACTAACTCTCCTACACC3GATTGGCGCGAAATTCGGGCCACTCAAACAACTCTGTGTAC3GCGAACATATAATCGCGAACAATGGCTGCAAGCTTAGCCAA3Round 11 (Sanger sequencing, 19 colonies)[GCGGTGCCAAGCCGTCGGGTTATGTTGATCTCCTCAAGGAC]{.ul}94.7GACTCTGATGCCTCAGACATTGACGCTTCCTGCGCAAGTTG5.3[^1]

Specificity and Affinity of the Selected RNA Aptamer RA16 *In Vitro* {#sec2.2}
--------------------------------------------------------------------

We performed several experiments to confirm the specificity of the best sequence (RA16) against NSCLC. NCI-H460 cells used for establishing the tumor model were employed for the target-binding studies *in vitro*.[@bib24], [@bib25], [@bib26] NCI-H460 cells incubated with Cy3-labeled RA16 showed strong fluorescent signal, indicating the specific binding between RA16 and NCI-H460 cells *in vitro*, whereas the negative control (initial RNA library) showed no detectable signal ([Figure 2](#fig2){ref-type="fig"}A). We further investigated the binding specificity of RA16 using other cell lines, including NSCLC cell lines (NCI-H1299, SPC-A1, and NCI-H1650) as well as non-NSCLC cell lines (293T and HeLa). For NSCLC cells, RA16 showed strong binding to both NCI-H460 and NCI-H1299 cells, but weak binding (∼5%) to NCI-H1650 cells as illustrated in [Figure 2](#fig2){ref-type="fig"}B by flow cytometry. The binding of RA16 toward SPC-A1 is minimal. In contrast to NSCLC cells, RA16 showed no binding to non-NSCLC 293T and HeLa cells. Moreover, no fluorescence was detected when HeLa cells and 293T cells were incubated with Cy3-labeled RA16 ([Figure 2](#fig2){ref-type="fig"}C). Notably, the labeling efficiencies of RA16 and RNA library by fluorescent dyes were comparable ([Table S1](#mmc1){ref-type="supplementary-material"}), indicating the difference from labeling is neglectable. These results demonstrate that RA16 is able to bind multiple NSCLC cell lines as an NSCLC-targeting aptamer.Figure 2Aptamer RA16 Demonstrates High Specificity to NCI-H460 Cell *In Vitro*(A) Fluorescence microscopy revealed binding of RNA sequences to NCI-H460 cells. NCI-H460 cells were incubated with Cy3-labeled RNA molecules, and images were captured after 1 hr incubation (20× objective; scale bar, 50 μm). (B) Flow cytometry to monitor aptamer binding to NSCLC cells and control cells. NCI-H460, HEK293T, HeLa, NCI-H1650, NCI-H1299, and SPC-A1 cells were incubated with FITC-labeled RNA molecules, and the fluorescence intensity was measured by flow cytometry. (C) Fluorescence microscopy revealed binding of aptamer RA16 to different cells. Images were captured after 1 hr incubation of cells with Cy3-labeled RA16 (10× objective; scale bar, 100 μm, BF represents images taken under bright field. (D) The binding curve of FITC-labeled RA16 (5--200 nM) and mean fluorescence intensities (MFIs) obtained by flow cytometry, K~D~ = 9 ± 2 nM. Three independent experiments were performed; all data represent means ± SD, n = 3.

We investigated the binding affinity of RA16 to NCI-H460 cells by determining the equilibrium dissociation constant (K~D~) using flow cytometry, the method widely used for characterizing the cell-SELEX aptamers.[@bib18], [@bib27] Analysis of the fitted curve revealed a K~D~ value of 9 ± 2 nM ([Figure 2](#fig2){ref-type="fig"}D) and was within the typical range displayed by aptamers,[@bib26], [@bib28] showing the high affinity of RA16 to NCI-H460 cells.

Specificity of Selected the RNA Aptamer RA16 *In Vivo* {#sec2.3}
------------------------------------------------------

Having confirmed the specificity and high affinity of RA16 to NCI-H460 cells *in vitro*, we performed experiments to evaluate specificity of RA16 in the xenograft mouse. Cryosections from various organs of tumor-bearing mouse were collected and incubated with FITC-RA16 to verify tissue specificity *in vitro*. Strong binding of RA16 to NCI-H460 tumors was observed, with only weak signal detected with normal lung tissues. No significant binding was detected in other tissues from tumor-bearing mouse or control mouse ([Figure 3](#fig3){ref-type="fig"}A), demonstrating the high specificity of RA16 to NSCLC tumors. We confirmed the targeting activity of RA16 in living animals with qRT-PCR to trap specific RA16 from various tissues of tumor-bearing mouse. The selected RNA aptamer RA16, or initial RNA library was administrated and its distribution level determined by qRT-PCR. Mouse 18S RNA was used as a standard for normalization. As shown in [Figure 3](#fig3){ref-type="fig"}B, the RA16 level was significantly higher (10- to 100-fold) in NCI-H460 tumors as compared to any other organs including heart, liver, spleen, lung, and kidney. Moreover, a significant difference was observed in aptamer recovery level in the tumor. In mouse tumors, the trapped RA16 was 44.3- ± 3.6-fold higher than the trapped initial RNA library. No significant enrichment of RA16 was observed in tissues from control mice ([Figure 3](#fig3){ref-type="fig"}C), indicating the specific entrapment of RA16 in the tumor tissue *in vivo*.Figure 3Aptamer RA16 Shows Specificity to NCI-H460 Tumor *In Vivo*(A) Cryosections from various organs of tumor-bearing mice were incubated with FITC-labeled RA16 or RNA library and photographed by microscope (10× objective; scale bar, 100 μm and applied to all images). (B) qRT-PCR was used to quantify RNA molecules in tumor, heart, liver, spleen, lung, and kidney. Mouse 18S RNA was used for normalization. All data represent means ± SD, n = 4. \*\*\*\*p \< 0.0005. (C) qRT-PCR analysis of RA16 distribution in mice bearing NCI-H460 tumor (n = 4) and healthy mice (n = 4). All data represent means ± SD, with 18S RNA used as a loading control. The black bars in (B) and (C) are the same results repeated. (D) *In vivo* imaging of Cy5.5-labeled RNA molecules in mice bearing NCI-H460 tumor at different time points (0.5, 2, and 3.5 hr post-injection).

We further performed an *in vivo* imaging assay to study RA16 binding in tumor-bearing mouse. The gradual movement of Cy5.5-labeled RA16 toward tumor sites was tracked. At 3.5 hr, RA16 was enriched at the tumor areas, as evident from the strong fluorescent signal at the tumor site. On the other hand, Cy5.5-labeled initial RNA library was enriched at other sites and degraded with time ([Figure 3](#fig3){ref-type="fig"}D). These results show that RNA aptamer RA16 was specific against human NCI-H460 cells and xenograft tumor tissues and showed high affinity both *in vitro* and *in vivo*.

Anti-tumor Efficacy of the Selected RNA Aptamer RA16 {#sec2.4}
----------------------------------------------------

Many aptamers are known to show inhibitory activities against their binding targets.[@bib29], [@bib30], [@bib31] To evaluate the anti-cancer of RA16, NCI-H460 cells were incubated with RA16 or scramble RNA (sequence in [Table S2](#mmc1){ref-type="supplementary-material"}) and the cell cytotoxicity determined after 48 hr. Aptamer RA16, but not scramble RNA control, inhibited cell proliferation by 75% at 300 nM concentration. Neither RA16 nor scramble RNA showed any inhibition on the proliferation of HeLa cells ([Figure 4](#fig4){ref-type="fig"}A). RA16 inhibited the cell growth of NCI-H460 in a dose-dependent manner. The inhibitory effect was observed from concentration of 10 nM, and its IC~50~ value was estimated to be ∼116.7 nM ([Figures 4](#fig4){ref-type="fig"}B and 4C). Under the same conditions, RA16 exhibited no inhibitory effect against HeLa cells even at 600 nM (data not shown).Figure 4Aptamer RA16 Inhibits NCI-H460 Cell Proliferation *In Vitro* and *In Vivo*(A) NCI-H460 and HeLa cells were evaluated with a standard CCK-8 assay after 48-hr incubation with 300 nM RA16 or scramble RNA. All data represent means ± SD, n = 6. \*\*\*\*p \< 0.0005. (B) NCI-H460 cells were evaluated with a standard CCK-8 assay after 48-hr incubation with different doses of RA16 or scramble RNA. All data represent means ± SD, n = 6. \*\*\*\*p \< 0.0005. (C) IC~50~ of RA16 to H460 cells. All data represent means ± SD, n = 6. (D) Mice bearing NCI-H460 tumor were treated with saline, scramble RNA, or RA16. The length (L) and width (W) of tumors were determined every 3 days and the tumor volume (V) calculated using the formula V = 1/2 × L × W^2^. Tumor growth was monitored from the start of the treatment. Results were expressed as mean tumor volume ± SEM (n = 5 per group, \*\*\*\*p \< 0.0005).

We further investigated the inhibitory effect of RA16 against NCI-H460-bearing mouse. Tumor sizes were measured every other day and tumor volumes calculated. On day 6, a significant reduction in tumor growth was observed in mice treated with RA16 as compared to those in the control group, whereas the control scramble RNA did not show any inhibitory effect on tumor growth ([Figure 4](#fig4){ref-type="fig"}D). The average inhibition rate for tumors of RA16-treated group was 54.26% ± 5.87% compared with those of the control group ([Table 2](#tbl2){ref-type="table"}), indicating that RA16 was able to inhibit NCI-H460 tumor growth *in vivo*.Table 2Tumor Inhibition RateGroupInhibition of RA16Inhibition of RA16-EPI AdductG1G2G3G1G2G3G4G5Negative Control (Saline)Scramble RNARA16Negative Control (Saline)EPIScramble RNA-EPI AdductRA16-EPI AdductAdduct w/o PEGylationTumor weight (g)------3.72 ± 0.672.03 ± 0.402.35 ± 0.251.33 ± 0.292.33 ± 0.34Inhibition rate (%)--3.6354.26--45.34 ± 10.8236.83 ± 6.7264.38 ± 7.9237.27 ± 9.14[^2]

Formation of RA16-Epirubicin Adduct {#sec2.5}
-----------------------------------

Like Dox, epirubicin (EPI) is known to be widely used in chemotherapies against various cancers, including NSCLC.[@bib32], [@bib33], [@bib34] It intercalates within double-stranded DNA strands through aromatic rings, in particular into double-stranded 5′-GC-3′ or 5′-CG-3′ sequences.[@bib35] Studies have shown that EPI is also capable to intercalate into double-stranded GC pairs of RNA aptamers.[@bib36] To explore the possibility of using the aptamer as a tumor-targeting carrier, we constructed an aptamer-EPI adduct for drug delivery studies. The two-dimensional structure of RA16 predicted by Mfold revealed eight possible sites for EPI intercalation ([Figure 5](#fig5){ref-type="fig"}A). Indeed, the fluorescence exhibited by EPI is quenched after intercalation into the aptamer, similar to that observed with doxorubicin (DOX).[@bib36], [@bib37] The formation of non-covalent adduct between RA16 and EPI was studies by measuring fluorescence. The fluorescence intensity was approximately 570 (a.u.) for free EPI; it decreased with the addition of increasing concentration of RA16. A steady minimum fluorescence was observed when the molar ratio of RA16 and EPI was 1:10 to 1:5 ([Figure 5](#fig5){ref-type="fig"}B). This observation is in agreement with the predicted eight intercalation sites, suggesting the non-covalent adduct of EPI to RA16 by intercalation into predicted double-stranded GC sequences. We also generated a scramble RNA that can presumably intercalate eight EPI molecules by forming RNA-EPI adduct as we measured through EPI fluorescence quenching (data not shown). We fixed the adduct molar ratio at 1:8 for subsequent *in vitro* and *in vivo* studies.Figure 5Aptamer RA16-EPI Adduct Enhances Specific Cytotoxicity to NCI-H460 Cell(A) Schema of EPI intercalation. EPI can be intercalated non-covalently into base pairs, in particular, the GC pair. (B) Determination of fluorescence of EPI and RA16-EPI adduct. Different ratios of RA16 and EPI adduct were tested for EPI fluorescence. The fluorescence of the adduct was quenched due to EPI intercalation into aptamer (λ~Ex~ = 485 nm, λ~Em~ = 580 nm). (C) Flow cytometry to monitor aptamer-EPI adduct binding to NCI-H460 cells. NCI-H460 cells were incubated with FITC-labeled aptamer-EPI adduct and the fluorescence intensity detected by flow cytometry. (D and E) NCI-H460 (D) and HeLa (E) cells were evaluated with a standard CCK-8 assay after 48-hr incubation under the following treatment conditions: untreated, 1.5 μM EPI, 187.5 μM RA16, 187.5 μM RA16-EPI adduct (RA16:EPI = 1:8), 187.5 μM scramble RNA, and 187.5 μM scramble RNA-EPI adduct (scramble RNA:EPI = 1:8). All data represent means ± SD, n = 5. \*\*\*\*p \< 0.0005, \*\*\*p \< 0.001, \*\*p \< 0.01, analyzed by one-way ANOVA and Tukey's test for multiple comparisons.

RA16-EPI Adduct Enhanced Specific Cytotoxicity against NCI-H460 *In Vitro* {#sec2.6}
--------------------------------------------------------------------------

Flow cytometry analysis was performed to assess the specificity of RA16-EPI adduct toward NCI-H460 cells. NCI-H460 cells exhibited a fluorescence shift when incubated with RA16-EPI, as compared with those treated with scramble RNA-EPI, demonstrating that RA16-EPI retained specific binding to NCI-H460 cells ([Figure 5](#fig5){ref-type="fig"}C).

We evaluated the anti-cancer efficacy of the adduct *in vitro*. As shown in [Figure 5](#fig5){ref-type="fig"}D, RA16-EPI demonstrated significantly higher inhibitory effects against NCI-H460 cells ([Figure 5](#fig5){ref-type="fig"}D). The inhibition rate was 85.20% ± 1.62% with RA16-EPI adduct as compared to 42.84% ± 1.67% and 54.86% ± 4.97% with free EPI (1.5 μM) and RA16 (0.1875 μM) alone, respectively, while scramble RNA-EPI exhibited an inhibition rate of 33.65% ± 5.14%, which was even less than the free EPI, presumably due to the capture of EPI by scramble RNA lack of cell targeting. These results strongly indicate the additive anti-cancer efficacy by RA16- EPI adduct.

To assess the side toxicity of RA16-EPI, we studied cell viability in non-targeted tumor cell line (HeLa cells) treated with RA16-EPI adduct. We observed that both RA16-EPI and scramble RNA-EPI were less cytotoxic to HeLa cells and the inhibition rate recorded were 71.91% ± 0.90% and 65.22% ± 3.43%, respectively, compared to 82.88% ± 0.90% with free EPI ([Figure 5](#fig5){ref-type="fig"}E).

RA16-EPI Adduct Enhanced Anti-tumor Efficacy in Animal Model {#sec2.7}
------------------------------------------------------------

To further evaluate efficacy of RA16-EPI adduct *in vivo*, first, we investigated the stability of RA16-EPI adduct and PEGylated RA16 in the serum *in vitro*. We first confirmed that during a 3 hr time period, the fluorescence intensity of free EPI degraded gradually; however, fluorescence of RA16-EPI adduct remained at a low level, indicating that EPI was intercalated into the RA16 structure in the presence of serum ([Figure 6](#fig6){ref-type="fig"}A). One critical question is whether the PEGylation of RA16 increases its *in vivo* stability. As illustrated in [Figure 6](#fig6){ref-type="fig"}B, more than 50% of PEGylated RA16 was still detected, whereas non-PEGylated RA16 disappeared almost completely after 1 hr incubation in 50% serum, demonstrating that PEGylated RA16 was more stable than non-PEGylated RA16 in serum.Figure 6RA16-EPI Adduct Enhances Cytotoxicity to NCI-H460 Xenograft Nude Mice(A) Stability of RA16-EPI adduct in the serum. Free EPI, RA16-EPI adduct, and serum were quantified by EPI fluorescence in the 20% serum. The fluorescence of EPI decreased with time, while that of RA16-EPI adduct remained quenched due to EPI intercalation (λ~Ex~ = 485 nm, λ~Em~ = 595 nm). (B) Stability of PEGylated RA16 in the serum. PEGylated or non-PEGylated RA16 was incubated with 50% serum, and survival of RNA molecules were monitored by 12% native-PAGE gel. (C) Mice bearing NCI-H460 tumor were treated with saline, EPI alone, scramble RNA-EPI adduct, RA16-EPI adduct, or adduct without PEG, and the length (L) and width (W) of the tumor determined every 3 days as follows: V = 1/2 × L × W^2^. Tumor growth was monitored from the start of the treatment. Results were expressed as mean tumor volumes ± SEM (n = 5 per group, \*\*\*\*p \< 0.0005, \*\*\*p \< 0.001, \*\*p \< 0.01, \*p \< 0.05), analyzed by two-way ANOVA followed by Tukey's test for multiple comparisons to saline. (D) Tumor weight was determined when mice were sacrificed at day 16 (n = 3--5 per group, \*\*\*p \< 0.001, \*p \< 0.05)

Based on the higher stability of intercalated EPI and PEGylated RA16 in the serum, we further evaluated the anti-cancer efficacy of PEGylated RA16-EPI in xenograft tumor models. On day 9, a decrease in tumor growth was observed for mice treated with EPI alone, PEGylated RA16-EPI adduct, PEGylated scramble RNA-EPI adduct or RA16-EPI adduct without (w/o) PEGylation ([Figure 6](#fig6){ref-type="fig"}C). PEGylated-RA16 should have higher *in vivo* stability and longer circulatory half-life and thereby exhibit higher levels of tumor reduction as compared to EPI alone, scramble RNA-EPI, or adduct w/o PEGylation ([Figure 6](#fig6){ref-type="fig"}C). On day 16, PEGylated RA16-EPI demonstrated a strong inhibition rate of 64.38% ± 7.92% as compared with the moderate inhibition observed with EPI alone (45.34% ± 10.83%), scramble RNA-EPI (36.83% ± 6.72%), or adduct w/o PEGylation (37.28% ± 9.14%) ([Figures 6](#fig6){ref-type="fig"}C and 6D; [Table 2](#tbl2){ref-type="table"}).

Discussion {#sec3}
==========

NSCLC is the leading cause of death from cancer all over the world.[@bib38] Chemotherapies---conventional treatment strategies used to prolong survival of patients---display severe adverse effects.[@bib3], [@bib4] RNA aptamers are considered as promising agents for targeted therapy, due to their high and specific target binding, small size, and low or non-immunogenicity. Over the years, aptamers with various potential applications against known targets such as vascular endothelial growth factor (VEGF), EGFR, mucin 1 (MUC1), and p53 have been developed.[@bib39], [@bib40], [@bib41], [@bib42] Aptamers are typically obtained from *in vitro* selection against various targets, including proteins, small molecules, or whole cells. A few investigations are based on *in situ* screening system.

In this study, we demonstrated that highly specific aptamers can be developed by direct *in vivo* selection from a diverse, PEGylated RNA library against NSCLC NCI-H460-bearing mouse, and the resulting aptamer can be used for targeted delivery of a therapeutic agent.

This is the first study to combine post-selection modification with *in vivo* screening platform. The smaller size of aptamers makes them more susceptible to renal filtration as compared to higher molecular weight antibodies. It was reported that the clearance time of 2′-fluoro aptamer was 5∼15 hr in plasma.[@bib21], [@bib43], [@bib44] Studies have shown the use of PEG to counter immune responses and extend the circulatory half-life of proteins, peptides, or other molecules.[@bib45], [@bib46] In addition, PEGylation may increase their persistence in the circulation. Macugen, the only aptamer that received FDA approval[@bib40], [@bib47] was introduced after PEGylation to overcome its rapid clearance and degradation *in vivo*. However, PEGylation may affect the structure and binding activity of the molecule *in vitro*.[@bib48], [@bib49] In this study, we used PEGylated RNA sequences during *in vivo* SELEX to extend the half-life of the RNA pool, reducing renal clearance and simplifying the post-selection modification process. Our studies demonstrated that the enriched aptamer, RA16, still possesses targeting activity after fluorescently labeling, EPI intercalation, and PEGylated modification.

During the selection, the starting library, a mixture containing diverse structures of RNA molecules, was served as the control to monitor the enhanced targeting activity by the enriched aptamer. To further investigate the cytotoxicity and efficacy of the aptamer, scramble RNA was used as control, which is uniform and stable.

Given the extremely high complexity of *in vivo* environments and the large amount of repertoires exposed to the initial library, we performed several selection rounds *in vivo*. In contrast to the studies by Mi[@bib19] and Cheng,[@bib20] the enriched sequence RA16 emerged after eight rounds of selection and accounted for 90% the enriched RNA after round 11. Our efficient enrichment and *in vivo* SELEX process could be attributed to the following possibilities: (1) PEGylation enhanced the persistence of the RNA pool in the circulation, thereby increasing the chances of enrichment of the specific aptamer, or (2) long circulatory time eliminated non-specific binding. In order to maximize the PEGylation, T7 RNA polymerase should preferentially use guanosine monophosphate (GMP) to initiate RNA transcription *in vitro*, since all the reagents were excessive in the reaction.[@bib50] Agarose gel results in [Figure 1](#fig1){ref-type="fig"}C demonstrated that more than 60%∼70% of the RNA library was successfully PEGylated, indicating the high diversity of the PEGylated RNA library were achieved. It is crucial to pre-optimize the selection strategy. The selection efficiency can be further improved by optimizing parameters such as the number of mouse used in each round, the ratio of RNA pool versus mouse number, assessment criteria, and tumor size.

We explored the application of the best aptamer RA16 as a carrier for targeted delivery of chemotherapeutics. Given the intercalatable property of EPI into G-C pairs, it was used to bind RA16 and form an aptamer-EPI adduct. Consistent with similar studies,[@bib15], [@bib27] RA16-EPI adduct demonstrated specificity and improved cytotoxicity upon incubation with NCI-H460 cells. In addition, the adduct demonstrated enhanced anti-cancer efficacy when used for targeting tumors *in vivo*. The enhanced efficacy may be attributed to PEGylated RA16 that served as a carrier for the chemotherapeutic, resulting in higher retention of EPI at tumor sites than elsewhere. Moreover, it allowed gradual release of EPI, leading to improved cytotoxicity and enhanced efficacy. However, no significant difference in the inhibitory effect was observed between EPI alone or adduct without PEGylation. The aptamer without PEGylation as a non-covalent carrier of EPI may be unstable *in vivo*, leading to quick leakage and clearance of the cargo. Furthermore, the concentration of the aptamer used (approximately 325 pmol) may be insufficient to demonstrate tumor regression by aptamer. Tumor suppression by PEGylated RA16-EPI adduct was relatively stronger than that by adduct w/o PEGylation. Thus, PEGylation is important to maintain stable tertiary structure and prolong aptamer circulation time *in vivo*, which may result in the accumulation of anti-cancer agents at tumor site.

In conclusion, we present a novel study demonstrating that aptamers can be selected from tumors of living animals and that the combination of PEGylation with *in vivo* SELEX improves the selection efficiency as well as greatly facilitates the post-selection applications. The specificity, high affinity, and strong anti-cancer efficacy of the aptamer RA16 strongly suggest its potential application for targeted diagnostics. In addition, we derived RA16-chemo adduct and explored its tumor-targeting potential for clinical applications. We believe that further identification of potential targets of this aptamer on cancer cells could facilitate our understanding of molecular mechanisms of NSCLC.

Materials and Methods {#sec4}
=====================

Cell Culture {#sec4.1}
------------

NCI-H460, HEK293T, and other cell lines obtained from Cell Resource Center of Shanghai Institutes for Biological Sciences, CAS, were cultured in RMPI-1640 medium supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/mL penicillin, and 100 mg/mL streptomycin in an incubator (Thermo Fisher Scientific, USA) at 37°C, 5% CO~2~. Cells were sub-cultured approximately every 2 days at 80% confluence using 0.25% (w/v) trypsin at a split ratio of 1:3.

Animals and Tumor Xenograft Models {#sec4.2}
----------------------------------

All animal studies were performed in accordance with the Guide for Care and Use of Laboratory Animals, Soochow University (IACUC Permit Number SYXK \[Su\] 2013-0105). To establish tumor xenograft model, female BALB/c nude mice (5 weeks old, SLRC Laboratory Animal Center, Shanghai, China) were sub-cutaneously injected in the underarm with 2 × 10^6^ NCI-H460 cells. The tumor size was determined with a vernier calliper and the tumor volume (V) calculated as V = 1/2 × L × W^2^, where L and W represent length and width of the tumor, respectively.

*In Vivo* Selection {#sec4.3}
-------------------

The starting RNA library containing 40 random nucleotides with NH~2~ at the 5′ end was generated by *in vitro* transcription with mutant (Y639F) T7 RNA polymerase from a pre-constructed DNA library ([Table 1](#tbl1){ref-type="table"}) from the Liu lab at UNC at 37°C for 8 hr in the following transcription reaction: 10 × transcription buffer (400 mM Tris-Cl, 80 mM magnesium chloride \[MgCl~2~\], and 20 mM spermidine), 10 mM ATP, 10 mM guanosine triphosphate (GTP) (Sangon Technologies, Shanghai, China), 10 mM 2′-F-dCTP/dUTP, 5 mM aminally-GMP (TriLink Biotechnologies, CA, USA), 10 mM dithiothreitol (DTT), 20 U T7 (Y639F) RNA polymerase, 20 U RiboLock RNase Inhibitor (Thermo Fisher Scientific, USA), and 0.05 U inorganic pyrophosphatase (Thermo Fisher Scientific, USA). The resultant reaction was treated with 2 μL DNase I (5 U/μL, RNase-free, TaKaRa, China) for 1 hr to eliminate template DNA. DNase I was inactivated with phenol-chloroform extraction. RNAs were then dissolved in 0.1 M sodium bicarbonate (NaHCO~3~ \[pH 8.3\]) and incubated with 30 kDa N-hydroxysuccinimide-PEG (NHS-PEG; PegBio, Jiangsu, China) for 2 hr at room temperature for PEG conjugation at the 5′ end ([Figure 1](#fig1){ref-type="fig"}C).

Prior to SELEX, 2 nmol RNA library was further desalted with Amicon YM-10 columns (Merck Millipore, Germany) and dissolved in 300 μL RNA refolding buffer (10 mM HEPES \[pH 7.4\], 50 mM NaCl, 1 mM CaCl~2~, 1 mM MgCl~2~, 2.7 mM KCl).[@bib13] The solution was refolded by incubation on a heat block at 90°C for 3 min, followed by slow cooling to room temperature.

The RNA library was injected by tail vein in three mice bearing NCI-H460 tumor. After 6 hr, mice were sacrificed and tumors harvested. Tumors were rinsed with Dulbecco's phosphate-buffered saline (DPBS), and total RNAs extracted by TRIzol reagent, followed by treatment with RNase A and DNase I at 37°C for 30 min to recover RNAs from the initial RNA library.

To regenerate DNA template for the next round of selection, the enriched RNAs were reversely transcribed with M-MLV reverse transcriptase (RNase H^−^) (TaKaRa, China) followed by PCR amplification. The number of PCR cycles was optimized and the cDNA pool was amplified in a Taq PCR reaction containing 0.4 μM each of 5′ and 3′ primers ([Table S2](#mmc1){ref-type="supplementary-material"}), 1.5 mM MgCl~2~, 80 μM of each deoxynucleotide triphosphate (dNTP), and 0.05 U/μL Taq DNA polymerase (Sangon Technologies, Shanghai, China). cDNA was purified and recycled by MiniBEST Agarose Gel DNA Extraction Kit (TaKaRa, China). Purified and amplified double-stranded DNA (dsDNA) pool was *in vitro* transcribed into RNA pool followed by PEGylation for the next round of selection, as described above.

After every three rounds of selection, recovered cDNAs were cloned into T-vector (TaKaRa, China) following the manufacturer's protocol and sequenced by Sangon Technologies (Shanghai, China).

Fluorescent Labeling of RNA Aptamers {#sec4.4}
------------------------------------

DNA templates of aptamers were *in vitro* transcribed into RNA by mutant T7 RNA polymerase and incorporated with aminoallyl-GMP (TriLink Biotechnologies, USA) to replace the 5′ end of GTP. After transcription, the reaction mixture was treated with 2 μL DNase I (5 U/μL, RNase-free) for 1 hr to eliminate the template DNA, followed by phenol-chloroform extraction to deactivate DNase I. To generate fluorescein-containing aptamers, RNA pellets were suspended in 0.1 M NaHCO~3~ (pH 8.3) and incubated with NHS-Cy3 (GE Healthcare, MA, USA), fluorescein isothiocyanate (FITC) (Life Technologies, USA) or NHS-Cy5.5 (GE Healthcare, MA, USA). Excess of fluorescent dye was neutralized with 10 mM Tris, and the solution was filtered using Amicon YM-10 filter to generate fluorescently labeled RNA transcripts. The absorption of the fluorescent dyes and RNAs were detected by One Drop to monitor the labeling efficiency.

Fluorescence Microscopy {#sec4.5}
-----------------------

NCI-H460, HeLa, and other cell lines were grown to 70% confluence on coverslips. These coverslips and mouse tissue cryosections were incubated with 200 nM fluorescent-labeled aptamer in HEPES-buffered saline (HBS) containing 1.0 μg/mL tRNA for 1 hr at 37°C. Cells were fixed with 4% paraformaldehyde for 10 min and washed thrice with DPBS. The nucleus was stained with Hoechst33342 (Thermo Fisher Scientific, USA) and cells imaged under a microscope (Olympus, Tokyo, Japan).

Flow Cytometry {#sec4.6}
--------------

NSCLC cells, HEK293T, and HeLa cells were grown to 70% confluence in 24-well plates, washed with HBS (RNA refolding buffer containing 1% BSA), and incubated with FITC-labeled aptamer in serum-free medium at 37°C for 2 hr. Cells were washed twice with DPBS and suspended in fluorescence-activated cell sorting (FACS) buffer (BD Bioscience, USA). Flow cytometry data were obtained using FACSVerse system (Becton Dickinson, NJ, USA), with 10,000 event acquisition for each sample and analyzed using FlowJo software (version X 10.0, <https://www.flowjo.com/>).

Fluorescence-Based K~D~ Determination {#sec4.7}
-------------------------------------

Cells were treated as above and incubated with series concentrations (0 to 200 nM) of FITC-labeled aptamer for FACS analysis. The mean fluorescence intensity (MFI) of samples was obtained to calculate the K~D~ value for the interaction between RA16 and NCI-H460 cell using the equation F = B~max~ × \[L\]/(K~D~ + \[L\]), where F = fluorescence intensity and \[L\] = concentration of FITC-RA16.[@bib18], [@bib27]

qRT-PCR for *In Vivo* Trap Assay {#sec4.8}
--------------------------------

Four mice were administered RA16 at 500 pmol concentration via tail vein. After 3.5 hr, RNAs were extracted from tumor, heart, liver, lung, spleen, and kidney using TRIzol reagent following the manufacturer's protocol. The amount of RNA was quantified (One Drop), and 500 ng DNase I-treated RNAs were used for reverse transcription using M-MLV transcriptase (TaKaRa, China). The relative abundance of RNA was quantified using qRT-PCR with appropriate primers and Power SYBR Green Master Mix (Life Technologies, USA) with StepOne Plus Real-Time PCR system (Applied Biosystems, USA). Mouse 18S RNA (primer sets from Sangon Technologies) was used for normalization.

*In Vivo* Imaging Study {#sec4.9}
-----------------------

Mice bearing NCI-H460 tumor were used for *in vivo* imaging assay. When the tumors size reached 200--300 mm^3^, mice were injected with Cy5.5-labeled aptamer at 1 nmol concentration via tail vein. Images were taken on IVIS Lumina Imaging system II (PerkinElmer, USA) at 0.5, 2, and 3.5 hr post-injection.

*In Vitro* Cytotoxicity {#sec4.10}
-----------------------

NCI-H460 and other cells (2 × 10^4^ cells per well) were seeded in 96-well plates. After 24 hr incubation, cells were treated with RA16 or scrambled aptamer (sequence in [Table S2](#mmc1){ref-type="supplementary-material"}) added in fresh medium at different concentrations. Following incubation for 48 hr, cell viability was determined as per the Cell Counting Kit-8 (CCK-8) protocol (Dojindo, Tokyo, Japan). Absorbance was measured at 450-nm wavelength using a microplate reader (Thermo Fisher Scientific, USA).

*In Vivo* Anti-tumor Efficacy {#sec4.11}
-----------------------------

Mice bearing NCI-H460 tumor were weighed and randomly divided into different groups when tumors reached a size of 50--100 mm^3^. The RNA molecules for treatment were generated by *in vitro* transcription with mutant (Y639F) T7 RNA polymerase from the DNA template as described above. Mice were administrated saline (control), 2 nmol scramble RNA or RA16 via intravenous injection on days 0, 3, 5, 7, and 9. Tumor size was measured every other day and tumor volume calculated as described above. At day 16, mice were sacrificed, tumors and other organs were collected and weighed, and the inhibition rate was measured.

Aptamer-EPI Adduct Formation {#sec4.12}
----------------------------

For non-covalent adduct of the aptamer to EPI, RA16 or scramble RNA was first dissolved in RNA refolding buffer, followed by 3-min incubation on a heat block at 90°C. The reaction mixture was slowly cooled to room temperature to form a uniform secondary structure. The aptamer was added into an EPI solution at various concentrations to obtain EPI/aptamer molar ratios of 100, 50, 25, 10, and 5. After 2 hr incubation, fluorescence of EPI was measured in a 96-well black plate using Synergy Neo Analyzer (excitation wavelength = 485 nm, emission wavelength = 580 nm, BioTek, USA). The adduct was freshly prepared before each experiment. For adduct, the molar ratio of RA16/scramble RNA and EPI was fixed at 1:8.

Cell Viability Evaluation {#sec4.13}
-------------------------

NCI-H460 and HeLa cells (2 × 10^4^ cells per well) were cultured in 96-well plates for 24 hr. Cells were treated with 1.5 μM EPI, 187.5 nM RA16, scramble RNA, RA16-EPI adduct, and scramble RNA-EPI adduct for 48 hr, followed by CCK-8 determination as described by the manufacturer's protocol. Absorbance was measured at 450 nm wavelength with a microplate reader (Thermo Fisher Scientific, USA).

Serum Stability of RA16-EPI Adduct {#sec4.14}
----------------------------------

To monitor the stability of RA16-EPI adduct in the serum, 3 μM EPI, 375 nM RA16-EPI, and vehicle control were incubated with 20% serum free of chelating agents. Fluorescence of free EPI was measured in a 96-well black plate by FilterMax F5 Multi-Mode Reader (excitation wavelength = 485 nm, emission wavelength = 595 nm, Molecular Devices, Austria). The adduct was freshly prepared for each experiment.

Serum Stability of PEGylated RA16 {#sec4.15}
---------------------------------

Five picomoles of PEGylated RA16 and non-PEGylated RA16 mixture was incubated in 50% serum without chelating agents, for 0 min, 10 min, 1 hr, 3 hr, and 12 hr, respectively. RA16 samples after incubation were then loaded onto a 12% native PAGE gel, followed by GelRed (Solarbio, Beijing, China) staining for visualization and quantification.

*In Vivo* Efficacy of RA16-EPI Adduct {#sec4.16}
-------------------------------------

Mice bearing NCI-H460 tumor were weighed and randomly divided into different groups after the tumor size reached 200--300 mm^3^. Mice (n = 5) from each group received either saline (control), free EPI (1.5 mg/kg), PEGylated RA16-EPI, PEGylated scramble RNA-EPI, or RA16-EPI w/o PEGylation (EPI at 1.5 mg/kg) weekly. Tumor size was measured every other day and tumor volume determined as described above. On day 16, mice were sacrificed, tumors and other organs were excised and weighed, and inhibition rate was monitored.

Statistical Analysis {#sec4.17}
--------------------

Each experiment was repeated at least thrice with duplication for each sample tested. Results are presented as means ± SD, unless otherwise indicated. Statistical analysis and graphs were generated by GraphPad PRISM (version 6, GraphPad, CA, USA). Statistical differences were evaluated using one-way ANOVA, unless otherwise indicated. A value of p \< 0.05 was considered statistically significant.
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[^1]: RA16 ranked first after rounds 8 and 11 (underlined).

[^2]: Inhibition rate (%) = (average tumor weight of control − average tumor weight of treated group)/average tumor weight of control × 100%.
